fosdenopterin hydrobromide · Sentynl Theraps Inc · NDA 214018
Nulibry
Earliest generic entry, as listed
9 Apr 2029
Blocked by patent: US 7504095.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7504095 | product, use U-3092 | 9 Apr 2029 |
Exclusivities · 1 unexpired
| ODE-342 | orphan drug (7 years) | 26 Feb 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214018 · 001 · RLD | powder, intravenous | EQ 9.5MG BASE/VIAL | 9 Apr 2029 |
Expired or delisted (1)
- NCE · 26 Feb 2026